The efficacy of BI-4020 was also evaluated in vivo, and a significant anti-tumor effect against the EGFR-del19/T790M/C797S/L718M quadruple mutant was confirmed using BI-4020 with an anti-EGFR antibody combination without any apparent side effects. The gene discussed is EGFR; the disease is neoplasm.